FLT3 and acute myeloid leukemia: In conclusion, although fewer studies looking at FLT3 have been performed on ALL than on AML, our results in combination with recent literature suggest that specific ALL subtypes and subgroups may also benefit from a deeper understanding of the biology of FLT3 alterations and their clinical implications.